Analysts Set MDxHealth SA (NASDAQ:MDXH) Target Price at $3.50

Shares of MDxHealth SA (NASDAQ:MDXH) have been assigned a consensus recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $3.50.

Several research firms recently issued reports on MDXH. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. BTIG Research lowered their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen lowered MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Lake Street Capital cut their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $0.42 on Tuesday. The company has a market capitalization of $20.69 million, a P/E ratio of -0.64 and a beta of 1.43. The stock’s 50 day moving average price is $0.55 and its 200 day moving average price is $2.08. MDxHealth has a 52 week low of $0.40 and a 52 week high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. As a group, sell-side analysts forecast that MDxHealth will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXH. Jump Financial LLC acquired a new position in MDxHealth during the fourth quarter valued at approximately $139,000. Millennium Management LLC acquired a new stake in shares of MDxHealth in the third quarter worth $127,000. Lazard Asset Management LLC bought a new stake in shares of MDxHealth during the 4th quarter worth $83,000. Bank of America Corp DE boosted its holdings in shares of MDxHealth by 5,164.0% during the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after buying an additional 14,769 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth during the 4th quarter worth $68,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.